Featured Archives - Page 13 of 14

Sep 21 2020

Arizona State University/Halberd Corp. Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen Re-Creation!

By Admin|2020-09-20T20:34:28-04:00September 21st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 21, 2020 – Halberd Corporation (OTC PINK: "HALB") released a progress update on the research being conducted in conjunction with Arizona State University researchers. Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. With this breakthrough, Dr. Chen’s team will ...

Sep 17 2020

Arizona State University/Halberd Corp. Outline Partnership 2nd Stage Goals of $1.4 M Covid-19 Program

By Admin|2020-09-17T08:26:31-04:00September 17th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 17, 2020 – Halberd Corporation (OTC PINK: "HALB") today outlined the specifics of the second stage goals of the $1.4 Million seven-phase research project with Arizona State University. The second stage of the research involves an investigation of a method using dialysis, or a variant of dialysis, to remove the fluorescent ...

Sep 14 2020

Halberd Corporation Outlines Multi-Phase $1.4 M Covid-19 Program in Partnership With ASU

By Admin|2020-09-13T20:36:48-04:00September 14th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 14, 2020 – Halberd Corporation (OTC PINK: "HALB") today released the specifics of the initial phase of the $1.4 Million seven-phase research project with Arizona State University. The University project for a rapid test to identify Covid-19 infection, from a sample such as saliva, mucus, blood and CSF will be based ...

Sep 8 2020

Halberd Corporation Research on Covid-19 Treatment Development Begins at ASU

By Admin|2020-09-08T11:19:17-04:00September 8th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 8, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU’s research focuses on the development of antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of ...

Sep 2 2020

Why Halberd Corporation Selected ASU And Where They Stand Among Other Universities

By Admin|2020-09-02T08:00:19-04:00September 2nd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 2, 2020 – Halberd Corporation (OTC PINK: "HALB") today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment. ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services ...

Aug 31 2020

Halberd Selects Arizona State University (ASU) to Develop Its Patented Covid-19 Treatment(s)

By Admin|2020-08-31T08:00:31-04:00August 31st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 31, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the signing of a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. The work will focus on developing antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications ...

Aug 27 2020

Halberd Corporation Selects University Research Partner

By Admin|2020-08-27T08:00:21-04:00August 27th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, August 27, 2020 – Halberd Corp. (OTC PINK: "HALB") is pleased to announce the successful completion of its search for a major research university partner. The University, to be announced, is engaged to develop compounds for use in Halberd’s patented extracorporeal treatment of Covid-19. Terms of the agreement have been finalized and ...

Aug 18 2020

Halberd Corporation CEO Answers Shareholders’ Questions Regarding Covid-19 Treatment

By Admin|2020-08-18T08:00:11-04:00August 18th, 2020|Featured, Investor News, News, Technology|0 Comments

Jackson Center, PA, August 18, 2020 – Halberd Corp. (OTC PINK: "HALB") Chairman, President & CEO of Halberd Corporation, William A. Hartman, has received a number of questions from shareholders regarding the extracorporeal process for treatment of Covid-19. Below, Mr. Hartman responds to those questions. Q: There are various extracorporeal medical procedures being researched or ...

Aug 10 2020

Halberd Corporation Adds Dr. Abdon Nanhay to Scientific Advisory Board

By Admin|2020-08-10T08:00:04-04:00August 10th, 2020|Featured, Investor News, News|0 Comments

Furthering the Fight Against Covid-19 Internationally Jackson Center, PA, August 10, 2020 – Halberd Corp. (OTC PINK: "HALB") today confirmed the addition of Dr. Abdon Nanhay as a member of the Scientific Advisory Board. Dr. Nanhay, a Brazilian physician, has over 25 years of experience in health and biological sciences. Dr. Nanhay’s experiences include general ...

Aug 4 2020

Halberd Corporation Secures $2 Million for Covid-19 Research

By Admin|2020-08-04T08:00:29-04:00August 4th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 4, 2020 – Halberd Corp. (OTC PINK: "HALB") announced today that they have secured non-dilutive, grant-based funding for their patent pending Covid-19 treatment(s). Newly formed Nonprofit Organization, Epidemiologic Solutions Corporation, a Louisiana, Internal Revenue Code Section 501(c)(3) application pending, has committed to provide funding of approximately $2,000,000, as required by Halberd ...

Previous 121314 Next